Curated News
By: NewsRamp Editorial Staff
January 13, 2026

Kamada Projects 13% Revenue Growth for 2026, Driven by Plasma Therapies

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Kamada Ltd. offers investors a competitive edge with projected 13% revenue and 23% EBITDA growth in 2026, driven by proprietary plasma therapies and market expansion.
  • Kamada's growth stems from organic expansion of its plasma-derived therapeutics and distribution segments, plus plasma collection from three Texas centers, reducing third-party dependency.
  • Kamada's plasma-derived therapies and global distribution improve patient access to critical treatments in over 30 countries, advancing healthcare worldwide.
  • Kamada's Texas plasma centers can collect 50,000 liters annually each, generating up to $10 million revenue at full capacity while supplying industry peers.

Impact - Why it Matters

This news matters because Kamada's projected growth reflects broader trends in the biopharmaceutical sector, where companies are increasingly focusing on self-sufficiency and diversification to mitigate risks like supply chain dependencies. For investors, the strong financial outlook, including double-digit revenue and EBITDA growth, signals potential stability and profitability in a competitive market. Patients and healthcare providers may benefit from Kamada's expansion of plasma-derived therapies, which are critical for treating rare diseases and immune disorders, potentially improving access and treatment options globally. Additionally, the company's move into plasma collection and distribution expansion could influence industry dynamics, encouraging more firms to invest in vertical integration to secure supply chains and reduce costs, ultimately impacting drug availability and pricing in regions like the Middle East and North Africa.

Summary

Kamada Ltd., a global biopharmaceutical company, is projecting robust financial growth for 2026, with revenue expected to reach $200-$205 million and adjusted EBITDA between $50-$53 million, representing year-over-year gains of 13% and 23% respectively. This optimistic outlook is driven by the company's diverse commercial portfolio, which includes specialty plasma-derived therapeutics like KAMRAB®, GLASSIA®, HEPAGAM®, and VARIZIG® marketed in over 30 countries, and its distribution segment that commercializes third-party biopharmaceutical products. Key players include CEO Amir London, who emphasizes the company's strong commercial and financial position, and Takeda Pharmaceutical Co. Ltd., which provides reduced royalty payments for GLASSIA that Kamada is overcoming through other growth avenues.

The company's growth strategy focuses on two main areas: expanding its specialty plasma-derived therapeutics business, particularly in the U.S. market, and leveraging its distribution segment through new biosimilar product launches in Israel and expansion into the Middle East and North Africa region. Additionally, Kamada is enhancing its self-sufficiency through its Kamada Plasma unit, which operates three plasma collection centers in Texas with significant capacity—each Houston and San Antonio site can collect approximately 50,000 liters annually, contributing $8-$10 million in revenue at full capacity. This move reduces dependency on third-party suppliers and positions Kamada as a supplier to industry peers, supporting its organic growth even amid challenges like reduced royalties from Takeda.

Beyond organic initiatives, Kamada is actively pursuing new business development deals and acquisitions to enrich its product portfolio and create synergies with existing operations. The company enters 2026 with about $75 million in cash from 2025, bolstering its ability to execute these plans. For more details on how Kamada is capitalizing on these opportunities, interested readers can click here. This news was originally published on Benzinga, with further disclosures available, and includes forward-looking statements subject to risks detailed in SEC filings, accessible at www.sec.gov. The original release can be viewed on www.newmediawire.com, highlighting the company's confidence in its growth trajectory and strategic positioning in the biopharmaceutical industry.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Kamada Projects 13% Revenue Growth for 2026, Driven by Plasma Therapies

blockchain registration record for this content.